Skip to main content

Table 3 Differences in ADAS-Cog, ADCS-ADL and MMSE scores in the CMA and placebo groups

From: Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial

Measurements

Patients

Placebo

CMA

CMA vs Placebo

Log2FoldChange

 

P value

 

Log2FoldChange

 

P value

 

Log2FoldChange

  

P value

  
  

Day 28 vs 0

Day 84 vs 0

Day 28 vs 0

Day 84 vs 0

Day 28 vs 0

Day 84 vs 0

Day 28 vs 0

Day 84 vs 0

Day 0

Day 28

Day 84

Day 0

Day 28

Day 84

ADAS-COG

All

− 0.159

− 0.191

0.009

0.001

− 0.327

− 0.371

3.2e-07

1.3e-05

− 0.200

− 0.368

− 0.379

0.317

0.111

0.179

 

High score

− 0.106

− 0.074

0.084

0.315

− 0.305

− 0.381

0.002

0.003

− 0.522

− 0.671

− 0.774

0.013

0.008

0.007

 

Low score

− 0.213

− 0.596

0.062

9.1e-06

− 0.387

− 0.449

3.7e-07

1.4e-04

− 0.011

− 0.218

0.143

0.886

0.119

0.478

 

MRI

− 0.131

− 0.233

0.170

0.022

− 0.262

− 0.391

5.9e-05

3.3e-04

− 0.388

− 0.520

− 0.546

0.159

0.100

0.135

ADCS-ADL

All

− 0.024

− 0.036

1.000

0.332

0.062

0.002

0.104

0.745

− 0.022

0.063

0.015

0.830

0.557

0.899

Mini Mental

All

0.078

0.108

0.043

0.022

0.087

0.048

0.015

0.120

0.115

0.124

0.055

0.225

0.249

0.627

  1. MMSE Mini mental state examination, ADAS-cog Alzheimer's disease assessment scale-cognitive subscale, ADCS-AD Alzheimer's disease cooperative study—activities of daily living, ADAS-Cog score > 20 is high, ≤ 20 is low; MRI Magnetic resonance imaging. Bold indicates statistical significance (P < 0.05)